Risks
4 risks
Risk Intelligence
Delay in EUGMP audit
View Risks →Zim Laboratories Ltd — Q3 FY26
Zim Laboratories reported Q3 FY26 operating income of ₹1,087 crore, with EBITDA of ₹145 crore (13.4% margin) and PAT of ₹44 crore, showing sequential improvement.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Zim Laboratories reported Q3 FY26 operating income of ₹1,087 crore, with EBITDA of ₹145 crore (13.4% margin) and PAT of ₹44 crore, showing sequential improvement. Export revenue surged 232% YoY to ₹961 crore, contributing 88% of revenue. The EUGMP remediation remains the top priority; management expects the audit in Q1 FY27 (April-June 2026). NIP product commercialization in regulated markets is delayed until EUGMP clearance, but emerging market traction continues. A preferential issue of ₹35 crore was completed to fund capex and compliance. Key risk: further delay in EUGMP audit could push back regulated market entry and NIP revenue inflection.
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Export Revenue
₹961M
+232% YoY
Export revenue grew significantly, contributing 88% of total operating income.
Inventory Days
94 days
flat
Inventory days remained stable at 94 days in Q3 FY26.
Receivable Days
105 days
flat
Receivable days stood at 105 days, consistent with prior periods.
R&D Spend
₹74M
flat
R&D expenditure of ₹74 million allocated for bio-studies and registrations.
Fast read
Guidance and risk preview
Management expects the EUGMP audit to occur in April-June 2026, with most CAPA responses submitted.
If the EUGMP audit is delayed beyond Q1 FY27, regulated market entry and NIP revenue inflection could be pushed out further.
View Risks →